Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GALT's Cash to Debt is ranked higher than
84% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. GALT: No Debt )
GALT' s 10-Year Cash to Debt Range
Min: 0.41   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GALT's Interest Coverage is ranked higher than
79% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. GALT: No Debt )
GALT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -816.21
GALT's ROE (%) is ranked lower than
59% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. GALT: -816.21 )
GALT' s 10-Year ROE (%) Range
Min: -830.47   Max: -63.92
Current: -816.21

-830.47
-63.92
ROA (%) -112.83
GALT's ROA (%) is ranked lower than
58% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. GALT: -112.83 )
GALT' s 10-Year ROA (%) Range
Min: -1711.47   Max: -50.18
Current: -112.83

-1711.47
-50.18
ROC (Joel Greenblatt) (%) -403466.67
GALT's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. GALT: -403466.67 )
GALT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -403466.67   Max: -1857.06
Current: -403466.67

-403466.67
-1857.06
EBITDA Growth (%) 11.50
GALT's EBITDA Growth (%) is ranked higher than
77% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. GALT: 11.50 )
GALT' s 10-Year EBITDA Growth (%) Range
Min: -22.1   Max: 11.5
Current: 11.5

-22.1
11.5
EPS Growth (%) 11.80
GALT's EPS Growth (%) is ranked higher than
77% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. GALT: 11.80 )
GALT' s 10-Year EPS Growth (%) Range
Min: -33.2   Max: 35.1
Current: 11.8

-33.2
35.1
» GALT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GALT Guru Trades in

GALT Guru Trades in

GALT Guru Trades in

Q1 2014

GALT Guru Trades in Q1 2014

George Soros 48,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with GALT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 New Buy0.01%$8.025 - $18.3 $ 13.55-3%48200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.80
GALT's P/B is ranked higher than
50% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. GALT: 10.80 )
GALT' s 10-Year P/B Range
Min: 0   Max: 457.5
Current: 10.8

0
457.5
EV-to-EBIT -21.31
GALT's EV-to-EBIT is ranked lower than
52% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. GALT: -21.31 )
GALT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -21.31

Current Ratio 18.97
GALT's Current Ratio is ranked higher than
98% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. GALT: 18.97 )
GALT' s 10-Year Current Ratio Range
Min: 0.2   Max: 20.63
Current: 18.97

0.2
20.63
Quick Ratio 18.97
GALT's Quick Ratio is ranked higher than
98% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. GALT: 18.97 )
GALT' s 10-Year Quick Ratio Range
Min: 0.2   Max: 20.63
Current: 18.97

0.2
20.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.60
GALT's Price/Net Cash is ranked higher than
91% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. GALT: 10.60 )
GALT' s 10-Year Price/Net Cash Range
Min: 4.96   Max: 221
Current: 10.6

4.96
221
Price/Net Current Asset Value 10.80
GALT's Price/Net Current Asset Value is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. GALT: 10.80 )
GALT' s 10-Year Price/Net Current Asset Value Range
Min: 4.96   Max: 732
Current: 10.8

4.96
732
Price/Tangible Book 10.80
GALT's Price/Tangible Book is ranked higher than
58% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. GALT: 10.80 )
GALT' s 10-Year Price/Tangible Book Range
Min: 4.87   Max: 516
Current: 10.8

4.87
516
Forward Rate of Return (Yacktman) -1.49
GALT's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. GALT: -1.49 )
GALT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -1.49

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PHPN.Germany
Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include major multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for GALT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of... Jul 22 2014
8:33 am Galectin Therapeutics announces first patient dosed in Cohort 1 of Phase 1B clinical trial... Jul 22 2014
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits Jul 22 2014
Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of... Jul 22 2014
Galectin Therapeutics Added to Russell 2000 Index Jul 09 2014
Galectin Therapeutics Added to Russell 2000 Index Jul 09 2014
Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs Jun 26 2014
BUZZ-U.S. Stocks on the Move-American Apparel, Willdan, Agile Therapeutics Jun 23 2014
Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is... Jun 23 2014
Galectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference May 29 2014
Galectin Therapeutics receives U.S. patent for GR-MD-02 May 28 2014
Galectin Therapeutics Receives U.S. Patent for GR-MD-02 in Diabetic Nephropathy, a Progressive... May 28 2014
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 28 2014
GALECTIN THERAPEUTICS INC Financials May 21 2014
Intercept Pharmaceuticals: Much Ado About Nothing? May 21 2014
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers May 20 2014
Nasdaq stocks posting largest percentage increases May 20 2014
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 16 2014
Intercept rises after analyst targets shares to more than double May 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide